Search

Displaying results 7901 - 7910 of 10000 in total
  1. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia® … Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of

    Products: XGEVA 120 MG SC. ENJEKSIYONLUK COZELTI ICEREN FLAKON, 4 ADET, XGEVA 120 MG SC. ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADET
  2. Drug

    Ofatumumab

    go.drugbank.com/drugs/DB06650
    ApprovedInvestigational

    Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. … [A6921] Ofatumumab is available for intravenous administration and is marketed as Arzerra.

    Products: İNFÜZYONLUK ÇÖZELTİ KONSATRESİ İÇEREN FLAKON (3 ADET), İNFÜZYONLUK ÇÖZELTİ KONSATRESİ İÇEREN FLAKON (1 ADET)
  3. Drug

    DiaPep 277

    go.drugbank.com/drugs/DB06651
    Investigational

    DiaPep 277 is a 24-mer laboratory-made peptide derived from Hsp60(437-460).

    Categories: Group I Chaperonins, Diabetes Mellitus, Type 1
  4. Drug

    Saredutant

    go.drugbank.com/drugs/DB06660
    Investigational

    Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

    Categories: Heterocyclic Compounds, 1-Ring, Receptors, Neurokinin-2, antagonists & inhibitors
  5. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    Gimatecan

    go.drugbank.com/drugs/DB06721
    Investigational

    Gimatecan is an orally available 7-t-butoxyiminomethyl-substituted lipophilic camptothecin derivative.

    Synonyms: (4S)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1-H-pyrano[3',4':6,7]-indolizino-[1,2-b]-quinoline-11-carbaldehyde O-(tert-butyl)-(E)-oxime, (4S)-11-[(E)-(tert-butoxyimino)methyl]-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
  7. Drug

    Ketobemidone

    go.drugbank.com/drugs/DB06738
    Investigational

    Ketobemidone is a powerful opioid analgesic. It also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids. … The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  8. Drug

    Seratrodast

    go.drugbank.com/drugs/DB06739
    Experimental

    Seratrodast (INN) is a thromboxane receptor antagonist used primarily in the treatment of asthma.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Inhibitors
  9. Drug

    Ginkgolide A

    go.drugbank.com/drugs/DB06743
    ExperimentalNutraceutical

    Ginkgolide A is a highly active PAF antagonist cage molecule that is isolated from the leaves of the Ginkgo biloba tree. Shows potential in a wide variety of inflammatory and immunological disorders.

    Synonyms: Ginkgolide-A
  10. Drug

    Ginsenoside C

    go.drugbank.com/drugs/DB06748
    ExperimentalNutraceutical

    Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 Enzyme Inhibitors